Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation

Authors: Linda Bouwman, Corien M. Eeltink, Otto Visser, Jeroen J. W. M. Janssen, Jolanda M. Maaskant

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Medication non-adherence is associated with poor health outcomes and increased health care costs. Depending on definitions, reported non-adherence rates in cancer patients ranges between 16 and 100%, which illustrates a serious problem. In malignancy, non-adherence reduces chances of achievement of treatment response and may thereby lead to progression or even relapse. Except for Chronic Myeloid Leukemia (CML), the extent of non-adherence has not been investigated in hematological-oncological patients in an outpatient setting. In order to explore ways to optimize cancer treatment results, this study aimed to assess the prevalence of self-administered medication non-adherence and to identify potential associated factors in hematological-oncological patients in their home situation.

Methods

This is an exploratory cross-sectional study, carried out at the outpatient clinic of the Department of Hematology at the VU University medical center, Amsterdam, the Netherlands between February and April 2014. Hematological-oncological outpatients were sent questionnaires retrieving information on patient characteristics, medication adherence, beliefs about medication, anxiety, depression, coping, and quality of life. We performed uni- and multivariable analysis to identify predictors for medication non-adherence.

Results

In total, 472 participants were approached of which 259 (55%) completed the questionnaire and met eligibility criteria. Prevalence of adherence in this group (140 male; 54,1%; median age 60 (18–91)) was 50%. In univariate analysis, (lower) age, (higher) education level, living alone, working, perception of receiving insufficient social support, use of bisphosphonates, depression, helplessness (ICQ), global health, role function, emotional function, cognitive function, social functioning, fatigue, dyspnea, diarrhea were found to be significantly related (p = <0.20) to medication non-adherence. In multivariable analysis, younger age, (higher) education level and fatigue remained significantly related (p = <0.10) to medication non-adherence.

Conclusions

This cross-sectional study shows that 50% of the participants were non-adherent. Lower age, living alone and perception of insufficient social support were associated factors of non-adherence in hematological-oncological adult patients in their home-situation.
Literature
1.
Fine RN, Becker Y, De Geest S, Eisen H, Ettenger R, Evans R, Rudow DL, McKay D, Neu A, Nevins T, Reyes J, Wray J, Dobbels F. Non-adherence consensus conference summary report. Am J Transplant. 2009;9:35–41.CrossRefPubMed
2.
3.
Wu EQ, Guerin A, Yu AP, Bollue VK, Guo A, Griffin JD. Retrospective real-world comparison of medical visits, costs and adherence between nilitinib and dasatinib in chronic myeloid leukaemia. Curr Med Res Opin. 2010;26(12):2861–9.CrossRefPubMed
4.
Leendertse AJ, Egberts ACG, Stoker LJ, van den Bemt PMLA. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008;168(17):1890–6.PubMed
5.
Sabaté, E. (2003). Adherence to long-term therapies, evidence for action. World Health Organization, apps.​who.​int/medicinedocs/pdf/s4883e/s4883e.pdf (Assessed at July 2, 2014).
6.
Foulon V, Schoffski P, Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg. 2011;66(2):85–96.PubMed
7.
Hall AE, Paul C, Bryant J, Lynagh MC, Rowlings P, Enjeti A, Small H. To adhere or not to adhere: rates and reasons of medication adherence in hematological cancer patients. Crit Rev Oncol Hematol. 2016;97:247–62.CrossRefPubMed
8.
Verbrugge M, Verhaegue S, Lauwaert K, Beeckman D, Hecke van A. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: systematic review. Cancer Treat Rev. 2013;39:610–21.CrossRef
9.
Puts MT, Tu HA, Tourangeau A, Howell D, Fitch M, Springall E, Alibhai SM. Factors influencing adherence to cancer treatment in older adults with cancer. A systematic review Annals of Oncology. 2014;25:564–77.CrossRefPubMed
10.
Efficace,,F., Baccarani, M., Rosti, G., Cottone, F., Castagnetti, F., Breccia, M., Alimena, G., Iurlo, A., Rossi, A. R., Pardini, S., Gherlinzoni, F., Salvucci, M., Tiribelli, M., Vignetti, M., Mandelli, F. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer. 2012;107(6):904–9.CrossRef
11.
12.
Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta-analysis of the association between adherence to drug therapy and mortality. Br Med J. 2006;333:15–21.CrossRef
13.
Marin, D., Bazeos, A., Mahon, F.X., Eliasson, L., Milojkovic, D., Bua, M., Apperley, J.F., Szydlo, R., Desai, R., Kozlowski, K., Paliompeis, C., Latham, V., Foroni, L., Molimard, M., Reid, A., Rezvani, K., Lavallade de, H., Guallar, C., Goldman, J., Khorashad, J.S. (2010). Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol, 28(14):2381–2388.
14.
Weingart, S.N., Brown, E., Bach, P.B., Eng, K., Johnson, S.A., Kuzel, T.M., Langbaum, T.S., Leedy, R.D., Muller, R.J., Newcomer, L.N., O'Brien, S., Reinke, D., Rubino, M., Saltz, L., Walters, R.S. (2008). NCCN task force report: oral chemotherapy. Journal of the National Comprehensive Cancer Network, 6 (sup. 3), s.1–14.
15.
Aisner, J. (2007). Overview of the changing paradigm in cancer treatment: oral chemotherapy. American Journal of Health-System Pharmacy, 64 (9) (sup 5) s. 4–7.
16.
Gater A, Heron L, Abetz-Webb L, Coombs J, Simmons J, Guilhot F, Rea D. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res. 2012;36:817–25.CrossRefPubMed
17.
Noens L, van Lierde M, De Bock R, Verhoef G, Zachée P, Berneman Z, Martiat P, Mineur P, van Eygen K, MacDonald K, de Geest S, Albrecht T, Abraham I. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401–11.CrossRefPubMed
18.
Fialko L, Garety PA, Kuipers E, Dunn G, Bebbington PE, Fowler D, Freeman D. A large-scale validation study of the medication adherence rating scale (MARS). Schizophr Res. 2008;100(1–3):53–9.CrossRefPubMed
19.
Thompson, K., Kulkarni, J., Sergejew, A.A. (2000) Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophrenia Research. 5; 42(3):241–247.
20.
Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14(1):1–24.CrossRef
21.
Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;46(6):555–67.CrossRef
22.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.CrossRefPubMed
23.
Bjellan I, Dahl AA, Haug T. The validity of the hospital anxiety and depression scale: an updated literature review. J Psychosom Res. 2002;52(2):69–77.CrossRef
24.
Spinhoven P, Ormel J, Sloekers PPA, Kempen GJM, Speckens AEM, Van Hemert AM. A validation study of the hospital anxiety and depression scale (HADS) in different groups of Dutch subjects. Psychol Med. 1997;27:363–70.CrossRefPubMed
25.
Evers, A.W.M., Kraaimaat, F.W., van Lankveld, W., Bijlsma, J.W.J. (1998). De Ziekte Cognitie Lijst (ZCL) (The Illness Cognition Questionnaire: ICQ). Gedragstherapie, 31:205–220.
26.
Evers AWM, Kraaimaat FW, van Lankveld W, Jongen PHJ, Jacobs WWG, Bijlsma JWJ. Beyond unfavorable thinking: illness cognition questionnaire for chronic diseases. J Consult Clin Psychol. 2001;69(6):1026–36.CrossRefPubMed
27.
Lauwerier E, Crombez G, Van Damme S, Goubert L, Vogelaers D, Evers AWM. The construct validity of the illness cognition questionnaire: the robustness of the three-factor structure across patients with chronic pain and chronic fatigue. International Journal of Behavioral Medicine. 2009;17:90–6.CrossRef
28.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F. The European organisation for research andbTreatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed
29.
30.
31.
Greenstein S, Siegal B. Compliance and noncompliance in patients with a functioning renal transplant: a multicenter study. Transplantation. 1998;66:1718.CrossRefPubMed
32.
De Vera, M.A., Marcotte, G., Rai, S., Galo, J.S., Bhole, V. (2014). Medication Adherence in Gout: A Systematic Review. Arthritis Care & Research, (Epub, ahead of print).
33.
StCharles M, Bollu VK, Hornyak E, Coombs J, Blanchette CM, DeAngelo DJ. Predictors of treatment non-adherence in patients treated with Imatinib Mesylate for chronic myeloid leukemia. Blood. 2009;114:2209.CrossRef
34.
Larizza MA, Dooley MJ, Kay SK, Kong DCM. Factors influencing adherence to molecular therapies in Haematology-oncology outpatients. Pharmacy practice and research. 2006;36(2)
35.
Geissler J, Sharf G, Bombaci F, Daban M, De Jong J, Gavin T, Pelouchova J, Dziwinski E, Hasford J, Hoffmann VS. Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries. Journal of Cancer Research and Clinical Oncology. 2017;143:1167–76.CrossRefPubMed
36.
Dobbels F, Vanhaecke J, Dupont L, Nevens F, Verleden G, Pirenne J, Geest de S. Pretansplant predictors of posttransplant adherence and clinical outcome: an evidence base for pretransplant psychosocial screening. Transplantation 27; 87(10). 2009:1497–504.
37.
De Marchi F, Medeot M, Fanin R, Tiribelli M. How could patient reported outcomes improve patient management in chronic myeloid leukemia? Expert Rev Hematol. 2017;10(1):9–14.CrossRefPubMed
38.
Timmers, L., Boons, C.C.L.M., Mangnus, D., Van de Ven, P.M., Van den Berg, P.H., Beeker, A., Swart, E.L., Honeywell, R.J., Peters, G. J., Boven, E., Hugtenburg, J.G. (2016). Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice. Frontiers in Pharmacol., Sep 21;7:310.
39.
Timmers L, Boons CCLM, Kropff F, van de Ven PM, Swart EL, Smit EF, Zweegman S, Kroep JR, Timmer-Bonte JNH, Boven E, Hugtenburg JG. Adherence and patients’ experiences with the use of oral anticancer agents. Acta Oncology. 2013;53(2):259–67.CrossRef
40.
Jönsson S, Olsson B, Söderberg J, Wadenvik H. Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study. Ann Hematol. 2012;91(5):679–85.CrossRefPubMed
Metadata
Title
Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation
Authors
Linda Bouwman
Corien M. Eeltink
Otto Visser
Jeroen J. W. M. Janssen
Jolanda M. Maaskant
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3735-1

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy

Research article

Effect of myeloid differentiation primary response gene 88 on expression profiles of genes during the development and progression of Helicobacter-induced gastric cancer

Research article

Subjective cognitive impairment and brain structural networks in Chinese gynaecological cancer survivors compared with age-matched controls: a cross-sectional study

Research article

Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial

Research article

Tumoral LINE-1 hypomethylation is associated with poor survival of patients with intrahepatic cholangiocarcinoma

Research article

Metabolic targeting of HIF-dependent glycolysis reduces lactate, increases oxygen consumption and enhances response to high-dose single-fraction radiotherapy in hypoxic solid tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits